Close
Xylem
Novotech

CirrusDx Laboratory receives emergency use authorisation from FDA for COVID-19 testing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Novartis and Antares Therapeutics Form Strategic Partnership for Cancer Drug Development

Novartis has finalized a significant collaboration agreement with Antares...
- Advertisement -

CirrusDx validated and will commercialize the Allplex 2019-nCoV Assay, a real-time Reverse Transcriptase PCR test developed by Seegene, a South Korea-based global leader in multiplex molecular diagnostics.

Cirrus Dx, an infectious disease laboratory and diagnostics company, received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) to perform SARS-COVID-19 testing.

CirrusDx validated and will commercialize the Allplexโ„ข 2019-nCoV Assay, a real-time Reverse Transcriptase PCR test developed by Seegene, a South Korea-based global leader in multiplex molecular diagnostics. The Seegene test can simultaneously detect three different genes (N, E and RdRP) of SARS-CoV-2, the virus responsible for COVID-19.

โ€œAs an infectious disease laboratory in the Washington D.C. area, there is a responsibility to serve the community at large,โ€ said Kyle Armantrout, Managing Director at CirrusDx. โ€œPartnering with Seegene to bring Allplexโ„ข 2019-nCoV Assay to high risk communities such as long-term care centers, and healthcare providers on the front lines, is mission critical for our organizations.โ€

The Allplexโ„ข 2019-nCoV Assay test will be performed in the CirrusDx CLIA High Complexity Laboratory with results reporting to clinicians within 24 hours of sample receipt.

Seegene is the worldโ€™s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics. Seegeneโ€™s core enabling technologies (DPOโ„ข, TOCEโ„ข, and MuDTโ„ข) form the foundation for its expansive portfolio of test panels that can simultaneously detect multiple targets in a single tube with high sensitivity, specificity and reproducibility. Seegeneโ€™s products and automation offer unparalleled throughput and cost savings. Seegeneโ€™s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics and oncology through its innovative proprietary technologies and AI-based assay design.

CirrusDx operates as a vertically integrated diagnostic company comprised of a CLIA High Complexity laboratory offering advanced diagnostics assays and diagnostics instrumentation.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Novartis and Antares Therapeutics Form Strategic Partnership for Cancer Drug Development

Novartis has finalized a significant collaboration agreement with Antares...

4 Health Supplement Brands Using Science-Backed Ingredients

Most supplement shoppers don't realize how wide the gap...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป